Form 4: Arcellx Chief Medical Officer Exercises Stock Options
SEC Form 4 Filing
Christopher Heery, Chief Medical Officer of Arcellx, Inc., reports exercising stock options and acquiring 22,556 shares of common stock on February 7, 2025.
Summary
- On February 7, 2025, Christopher Heery, the Chief Medical Officer of Arcellx, Inc., exercised restricted stock units (RSUs).
- This transaction resulted in the acquisition of 22,556 shares of Arcellx's common stock.
- Following the reported transaction, Heery directly owns 47,641 shares of Arcellx common stock.
- The RSUs vest over three years from the grant date of February 7, 2022, with one-third vesting each year.
Sentiment
Score: 5
Explanation: This is a neutral report on stock option exercises, a routine part of executive compensation. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency into the holdings of key personnel.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it slightly increases the number of outstanding shares.
Key Dates
| Date | Description |
|---|---|
| February 7, 2022 | RSU Grant Date; vesting commences |
| February 7, 2025 | Date of transaction (exercise of stock options) |
| February 11, 2025 | Date of report filing |
Keywords
Arcellx, Christopher Heery, Chief Medical Officer, Stock Options, Form 4, Beneficial Ownership, ACLX, Restricted Stock Units, Equity Incentive Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.